Global Whole Cell Cholera Vaccine Market Overview
Whole cell cholera vaccines are critical in preventing outbreaks of cholera, particularly in regions with poor sanitation and limited healthcare infrastructure. The market is shaped by global health initiatives, government vaccination programs, and partnerships between pharmaceutical companies and international organizations.
Segments Analysis
· By Type:
o For Adults
o For Children
o Combination Vaccines (added segment – cholera + other enteric diseases)
· By Application:
o Clinical Research Institutes
o Hospitals
o Surgical Centers
o Public Health Programs (added segment – mass immunization campaigns)
o NGOs & International Aid Organizations (added segment)
Regional Analysis
· North America: Limited demand; focus on travelers and military personnel.
· Europe: Moderate demand; vaccines used for travelers and humanitarian workers.
· Asia‑Pacific: Largest market; India, Bangladesh, and Southeast Asia drive demand due to endemic cholera.
· South America: Brazil and Haiti show demand linked to outbreaks.
· Middle East & Africa: High demand in cholera‑prone regions; WHO and UNICEF programs drive adoption.
Porter’s Five Forces
· Supplier Power: Moderate — few specialized vaccine manufacturers.
· Buyer Power: High — governments and NGOs purchase in bulk for immunization programs.
· Threat of New Entrants: Low — high R&D costs and strict regulatory requirements.
· Threat of Substitutes: Low — limited alternatives to cholera vaccines.
· Competitive Rivalry: Moderate — few global players dominate, but competition exists in regional supply.
SWOT Analysis
· Strengths: Proven efficacy; essential for outbreak control; strong support from global health organizations.
· Weaknesses: Limited commercial profitability; cold chain requirements; side effects in some populations.
· Opportunities: Expansion in endemic regions; integration with other enteric disease vaccines; government funding.
· Threats: Regulatory delays; competition from newer oral cholera vaccines; logistical challenges in rural areas.
Trend Analysis
· Rising demand for oral cholera vaccines in mass immunization campaigns.
· Growth of public‑private partnerships for vaccine distribution.
· Increasing focus on combination vaccines for broader protection.
· Expansion of cold chain infrastructure in developing countries.
· WHO and UNICEF initiatives driving global vaccination coverage.
Drivers & Challenges
Drivers:
· Rising incidence of cholera in endemic regions.
· Global health initiatives and funding from organizations like WHO, UNICEF, and Gavi.
· Advances in vaccine formulation and delivery methods.
Challenges:
· Cold chain logistics in rural and remote areas.
· Limited profitability for manufacturers.
· Regulatory hurdles and long approval timelines.
Value Chain Analysis
1. Research & Development — vaccine formulation, clinical trials.
2. Manufacturing — large‑scale production under GMP standards.
3. Distribution — cold chain logistics, government procurement.
4. Administration — hospitals, clinics, NGOs, mass campaigns.
5. Monitoring & Reporting — efficacy tracking, adverse event monitoring.
Highest value capture: government contracts and NGO partnerships for mass immunization programs.
Expanded Key Players
· SBL Vaccine
· PaxVax Inc.
· Valneva SE
· GlaxoSmithKline Plc.
· Johnson & Johnson
· Merck & Co. Inc.
· Pfizer Inc.
· Sanofi Pasteur
· AstraZeneca Plc. (MedImmune LLC)
· Serum Institute of India Pvt. Ltd.
· Bharat Biotech (India)
· Biological E Limited (India)
· Incepta Vaccine Ltd. (Bangladesh)
· EuBiologics (South Korea)
Quick Recommendations for Stakeholders
· Manufacturers: Focus on oral formulations, combination vaccines, and partnerships with NGOs.
· Governments: Strengthen cold chain infrastructure and outbreak preparedness programs.
· Investors: Target companies with regional dominance in endemic markets.
· Policy Makers: Support funding for vaccination campaigns and faster regulatory approvals.
· Healthcare Providers: Prioritize mass immunization in cholera‑prone regions.
Competitor Pipeline Matrix – Whole Cell Cholera Vaccine
|
Company |
Formulation Type |
Geographic Focus |
Stage of Development |
Key Strengths |
Limitations |
|
SBL Vaccine |
Oral whole cell |
India, South Asia |
Commercialized |
Affordable, regional presence |
Limited global distribution |
|
PaxVax Inc. |
Oral vaccine |
North America, Europe |
Commercialized |
Strong traveler vaccine market |
Smaller footprint in endemic regions |
|
Valneva SE |
Oral vaccine |
Europe, Asia |
Commercialized |
Partnerships with WHO, UNICEF |
Limited production scale |
|
GlaxoSmithKline (GSK) |
Oral + combination |
Global |
Advanced pipeline, commercialized |
Strong R&D, global distribution |
High pricing, regulatory delays |
|
Johnson & Johnson |
Injectable + oral |
Global |
Clinical trials, partnerships |
Strong global presence |
Focused more on other vaccines |
|
Merck & Co. Inc. |
Oral vaccine |
North America, Europe |
Clinical pipeline |
Strong R&D, advanced formulations |
Limited cholera‑specific focus |
|
Pfizer Inc. |
Oral vaccine |
Global |
Early pipeline |
Strong biotech capabilities |
Cholera not core portfolio |
|
Sanofi Pasteur |
Oral vaccine |
Global |
Commercialized |
Strong distribution networks |
Competition from regional players |
|
AstraZeneca (MedImmune) |
Oral vaccine |
Global |
Clinical pipeline |
Advanced biotech research |
Limited cholera focus |
|
Serum Institute of India |
Oral vaccine |
Asia, Africa |
Commercialized |
Largest vaccine producer, affordable pricing |
Dependent on government contracts |
|
Bharat Biotech |
Oral vaccine |
India, Africa |
Commercialized |
Strong in endemic regions |
Limited global reach |
|
Biological E Limited |
Oral vaccine |
India, South Asia |
Clinical pipeline |
Affordable formulations |
Smaller global presence |
|
Incepta Vaccine Ltd. |
Oral vaccine |
Bangladesh, Asia |
Commercialized |
Regional dominance |
Limited export capacity |
|
EuBiologics |
Oral vaccine |
South Korea, Asia |
Commercialized |
WHO prequalification, strong exports |
Smaller scale compared to big pharma |
Key Insights
- Global giants (GSK, Sanofi, J&J, Merck, Pfizer, AstraZeneca) dominate R&D and global distribution but face regulatory and pricing challenges.
- Regional leaders (Serum Institute, Bharat Biotech, Incepta, EuBiologics) provide affordable vaccines, crucial for endemic regions.
- WHO prequalification is a major differentiator for companies supplying mass immunization campaigns.
Recommendations for Stakeholders
- Governments & NGOs: Partner with regional producers (Serum Institute, Bharat Biotech, EuBiologics) for affordable mass campaigns.
- Investors: Focus on global players with advanced pipelines (GSK, Sanofi, Pfizer) for long‑term growth.
- Policy Makers: Support cold chain infrastructure and faster approvals to expand vaccine reach.
- Healthcare Providers: Prioritize oral formulations for ease of administration in mass campaigns.
1. Market Overview of Whole Cell Cholera Vaccine
1.1 Whole Cell Cholera Vaccine Market Overview
1.1.1 Whole Cell Cholera Vaccine Product Scope
1.1.2 Market Status and Outlook
1.2 Whole Cell Cholera Vaccine Market Size by Regions:
1.3 Whole Cell Cholera Vaccine Historic Market Size by Regions
1.4 Whole Cell Cholera Vaccine Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Whole Cell Cholera Vaccine Sales Market by Type
2.1 Global Whole Cell Cholera Vaccine Historic Market Size by Type
2.2 Global Whole Cell Cholera Vaccine Forecasted Market Size by Type
2.3 For Adults
2.4 For Children
3. Covid-19 Impact Whole Cell Cholera Vaccine Sales Market by Application
3.1 Global Whole Cell Cholera Vaccine Historic Market Size by Application
3.2 Global Whole Cell Cholera Vaccine Forecasted Market Size by Application
3.3 Clinical Research Institutes
3.4 Hospital
3.5 Surgical Centers
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Whole Cell Cholera Vaccine Production Capacity Market Share by Manufacturers
4.2 Global Whole Cell Cholera Vaccine Revenue Market Share by Manufacturers
4.3 Global Whole Cell Cholera Vaccine Average Price by Manufacturers
5. Company Profiles and Key Figures in Whole Cell Cholera Vaccine Business
5.1 SBL Vaccine
5.1.1 SBL Vaccine Company Profile
5.1.2 SBL Vaccine Whole Cell Cholera Vaccine Product Specification
5.1.3 SBL Vaccine Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.2 PaxVax Inc.
5.2.1 PaxVax Inc. Company Profile
5.2.2 PaxVax Inc. Whole Cell Cholera Vaccine Product Specification
5.2.3 PaxVax Inc. Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.3 Valneva SE
5.3.1 Valneva SE Company Profile
5.3.2 Valneva SE Whole Cell Cholera Vaccine Product Specification
5.3.3 Valneva SE Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.4 GlaxoSmithKline Plc.
5.4.1 GlaxoSmithKline Plc. Company Profile
5.4.2 GlaxoSmithKline Plc. Whole Cell Cholera Vaccine Product Specification
5.4.3 GlaxoSmithKline Plc. Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.5 Johnson and Johnson
5.5.1 Johnson and Johnson Company Profile
5.5.2 Johnson and Johnson Whole Cell Cholera Vaccine Product Specification
5.5.3 Johnson and Johnson Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.6 Merck and Co. Inc.
5.6.1 Merck and Co. Inc. Company Profile
5.6.2 Merck and Co. Inc. Whole Cell Cholera Vaccine Product Specification
5.6.3 Merck and Co. Inc. Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.7 Pfizer Inc.
5.7.1 Pfizer Inc. Company Profile
5.7.2 Pfizer Inc. Whole Cell Cholera Vaccine Product Specification
5.7.3 Pfizer Inc. Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.8 Sanofi Pasteur
5.8.1 Sanofi Pasteur Company Profile
5.8.2 Sanofi Pasteur Whole Cell Cholera Vaccine Product Specification
5.8.3 Sanofi Pasteur Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.9 AstraZeneca Plc.(Medimmune
5.9.1 AstraZeneca Plc.(Medimmune Company Profile
5.9.2 AstraZeneca Plc.(Medimmune Whole Cell Cholera Vaccine Product Specification
5.9.3 AstraZeneca Plc.(Medimmune Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.10 LLC.)
5.10.1 LLC.) Company Profile
5.10.2 LLC.) Whole Cell Cholera Vaccine Product Specification
5.10.3 LLC.) Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
5.11 Serum Institute of India Pvt.Ltd.
5.11.1 Serum Institute of India Pvt.Ltd. Company Profile
5.11.2 Serum Institute of India Pvt.Ltd. Whole Cell Cholera Vaccine Product Specification
5.11.3 Serum Institute of India Pvt.Ltd. Whole Cell Cholera Vaccine Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Whole Cell Cholera Vaccine Market Size
6.2 North America Whole Cell Cholera Vaccine Key Players in North America
6.3 North America Whole Cell Cholera Vaccine Market Size by Type
6.4 North America Whole Cell Cholera Vaccine Market Size by Application
7. East Asia
7.1 East Asia Whole Cell Cholera Vaccine Market Size
7.2 East Asia Whole Cell Cholera Vaccine Key Players in North America
7.3 East Asia Whole Cell Cholera Vaccine Market Size by Type
7.4 East Asia Whole Cell Cholera Vaccine Market Size by Application
8. Europe
8.1 Europe Whole Cell Cholera Vaccine Market Size
8.2 Europe Whole Cell Cholera Vaccine Key Players in North America
8.3 Europe Whole Cell Cholera Vaccine Market Size by Type
8.4 Europe Whole Cell Cholera Vaccine Market Size by Application
9. South Asia
9.1 South Asia Whole Cell Cholera Vaccine Market Size
9.2 South Asia Whole Cell Cholera Vaccine Key Players in North America
9.3 South Asia Whole Cell Cholera Vaccine Market Size by Type
9.4 South Asia Whole Cell Cholera Vaccine Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Whole Cell Cholera Vaccine Market Size
10.2 Southeast Asia Whole Cell Cholera Vaccine Key Players in North America
10.3 Southeast Asia Whole Cell Cholera Vaccine Market Size by Type
10.4 Southeast Asia Whole Cell Cholera Vaccine Market Size by Application
11. Middle East
11.1 Middle East Whole Cell Cholera Vaccine Market Size
11.2 Middle East Whole Cell Cholera Vaccine Key Players in North America
11.3 Middle East Whole Cell Cholera Vaccine Market Size by Type
11.4 Middle East Whole Cell Cholera Vaccine Market Size by Application
12. Africa
12.1 Africa Whole Cell Cholera Vaccine Market Size
12.2 Africa Whole Cell Cholera Vaccine Key Players in North America
12.3 Africa Whole Cell Cholera Vaccine Market Size by Type
12.4 Africa Whole Cell Cholera Vaccine Market Size by Application
13. Oceania
13.1 Oceania Whole Cell Cholera Vaccine Market Size
13.2 Oceania Whole Cell Cholera Vaccine Key Players in North America
13.3 Oceania Whole Cell Cholera Vaccine Market Size by Type
13.4 Oceania Whole Cell Cholera Vaccine Market Size by Application
14. South America
14.1 South America Whole Cell Cholera Vaccine Market Size
14.2 South America Whole Cell Cholera Vaccine Key Players in North America
14.3 South America Whole Cell Cholera Vaccine Market Size by Type
14.4 South America Whole Cell Cholera Vaccine Market Size by Application
15. Rest of the World
15.1 Rest of the World Whole Cell Cholera Vaccine Market Size
15.2 Rest of the World Whole Cell Cholera Vaccine Key Players in North America
15.3 Rest of the World Whole Cell Cholera Vaccine Market Size by Type
15.4 Rest of the World Whole Cell Cholera Vaccine Market Size by Application
16 Whole Cell Cholera Vaccine Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Segments Analysis
· By Type:
o For Adults
o For Children
o Combination Vaccines (added segment – cholera + other enteric diseases)
· By Application:
o Clinical Research Institutes
o Hospitals
o Surgical Centers
o Public Health Programs (added segment – mass immunization campaigns)
o NGOs & International Aid Organizations (added segment)
Regional Analysis
· North America: Limited demand; focus on travelers and military personnel.
· Europe: Moderate demand; vaccines used for travelers and humanitarian workers.
· Asia‑Pacific: Largest market; India, Bangladesh, and Southeast Asia drive demand due to endemic cholera.
· South America: Brazil and Haiti show demand linked to outbreaks.
· Middle East & Africa: High demand in cholera‑prone regions; WHO and UNICEF programs drive adoption.
